Pricing and Reimbursement of Pharmaceutical Products in France

Abstract

This article highlights the pricing and reimbursement approval process in France. A product approved on the grounds of its safety, quality, and efficacy cannot be launched before it has passed, and been approved by, the Transparency Commission and a price has been agreed upon with the Pricing Committee. The reimbursement dossier is usually submitted to the Transparency Commission after the license has been obtained. These two committees, and how they make pricing and reimbursement decisions, are detailed. It is expected that both pricing and reimbursement decisions in France will become more stringent.